Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deflux in gastroesophageal reflux disease
NCT01400945Phase 3
Key facts
- Status
- Completed
- Start
- Dec 2009
- Primary completion
- Aug 2011
- Countries
- 1
- Modality
- Polymer-based Nanoparticles, Hydrogel Systems
- Drugs
- dextranomer
- Conditions
- gastroesophageal reflux disease (GERD)
01
Overview
Phase 3, randomised, double-blind trial of dextranomer in gastroesophageal reflux disease (GERD), sponsored by Ahn-Gook Pharmaceutical Co., Ltd. Primary endpoint: Healing of erosive esophagitis at 4 weeks. Started Dec 2009; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 18-75 with endoscopically proven erosive esophagitis (LA grade A or higher) and typical reflux symptoms for at least 3 months.
04
Endpoints
Primary
Healing of erosive esophagitis
Beyond the preview
Go deeper on NCT01400945.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01400945.